[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU6522486A - Recombinant apolipoproteins and methods - Google Patents

Recombinant apolipoproteins and methods

Info

Publication number
AU6522486A
AU6522486A AU65224/86A AU6522486A AU6522486A AU 6522486 A AU6522486 A AU 6522486A AU 65224/86 A AU65224/86 A AU 65224/86A AU 6522486 A AU6522486 A AU 6522486A AU 6522486 A AU6522486 A AU 6522486A
Authority
AU
Australia
Prior art keywords
methods
recombinant apolipoproteins
apolipoproteins
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65224/86A
Inventor
Joanne B. Mallory
Andrew A. Protter
Karen D. Talmadge
Jean-Louis Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotechnology Research Partners Ltd
Original Assignee
Biotechnology Research Partners Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnology Research Partners Ltd filed Critical Biotechnology Research Partners Ltd
Publication of AU6522486A publication Critical patent/AU6522486A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU65224/86A 1985-10-04 1986-10-02 Recombinant apolipoproteins and methods Abandoned AU6522486A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78441885A 1985-10-04 1985-10-04
US784418 1985-10-04
US80469285A 1985-12-04 1985-12-04
US804692 1985-12-04

Publications (1)

Publication Number Publication Date
AU6522486A true AU6522486A (en) 1987-04-24

Family

ID=27120281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65224/86A Abandoned AU6522486A (en) 1985-10-04 1986-10-02 Recombinant apolipoproteins and methods

Country Status (3)

Country Link
EP (1) EP0239631A4 (en)
AU (1) AU6522486A (en)
WO (1) WO1987002062A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
EP0347915A3 (en) * 1988-06-23 1991-03-20 The Rockefeller University Method and agents for inhibiting low density lipoprotein synthesis
EP0394409B1 (en) 1988-09-02 1997-06-11 The Rockefeller University Macrophage-derived inflammatory mediator (mip-2)
IT1229996B (en) * 1989-04-20 1991-09-20 Cesare Sirtori EXPRESSION OF APOLIPOPROTEIN AI AND APOLIPOPROTEIN AI-MILAN IN YEAST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE APOLIPOPROTEINS.
FR2666813A1 (en) * 1990-09-18 1992-03-20 Rhone Poulenc Sante MICROBIOLOGICAL PROCESS FOR THE PREPARATION OF HUMAN AIV APOLIPOPROTEIN OR DERIVATIVES THEREOF.
ES2283007T3 (en) * 1995-11-09 2007-10-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services USE OF LECITINE CHOLESTEROL ACILTRANSPHERASE (LCAT) IN THE TREATMENT OF ATEROSCLEROSIS.
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
CA2401755A1 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
JP3944083B2 (en) 2001-05-15 2007-07-11 株式会社Ｊｉｍｒｏ High density lipoprotein reactive peptide
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
DK1964571T3 (en) 2007-03-01 2012-08-13 Csl Ltd Treatment of endothelial dysfunction in diabetic patients
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
JP5685529B2 (en) 2008-06-13 2015-03-18 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． Complexes for the administration of compounds having biological activity
ES2666701T3 (en) 2008-11-10 2018-05-07 Arbutus Biopharma Corporation New lipids and compositions for the delivery of therapeutic agents
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
EP3424939A1 (en) 2009-03-02 2019-01-09 Alnylam Pharmaceuticals Inc. Nucleic acid chemical modifications
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
CA3151387A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
LT2440183T (en) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Improved lipid formulation
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
ES2749426T3 (en) 2009-12-18 2020-03-20 Univ British Columbia Nucleic Acid Administration Methods and Compositions
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
KR101967411B1 (en) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 Biodegradable lipids for the delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN110123830A (en) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
EP2663548B1 (en) 2011-01-11 2017-04-05 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
JP6250543B2 (en) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド Dialiphatic substituted PEGylated lipids
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
AU2015364508A1 (en) 2014-12-18 2017-07-06 Alnylam Pharmaceuticals, Inc. ReversirTM compounds
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU542264B2 (en) * 1979-06-01 1985-02-14 G.D. Searle & Co. Plasmid vectors
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
CA1340597C (en) * 1984-08-27 1999-06-22 Haim Aviv Expression vectors containing pl promoter, and engineered restriction site for convenient replacement of ribosomal binding site, plasmids containing the vectors, hosts containing the plasmids and related methods
EP0217822B1 (en) * 1985-02-13 1993-05-12 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems

Also Published As

Publication number Publication date
EP0239631A1 (en) 1987-10-07
EP0239631A4 (en) 1989-01-12
WO1987002062A1 (en) 1987-04-09

Similar Documents

Publication Publication Date Title
AU6522486A (en) Recombinant apolipoproteins and methods
AU5274386A (en) Peptidylaminodiols
AU5184886A (en) Somatostatines
AU5882886A (en) Antianaphylactic and antibronchospastic N-benzhydryldiazacycloalkylalkananilides
AU5391286A (en) Trechter
AU569194B2 (en) 5-hydroxy-2-amino-pyrimidines
AU576466B2 (en) Novel 4h-1-benzopyran-4-ones and benzothiopyran-4-ones
AU590016B2 (en) Peptides
AU5224286A (en) Spiro-dioxolanes, - dithiolanes and-oxothiolanes
AU5313686A (en) Verktygsstal
AU5519386A (en) Epicondylitis-bandage
AU6145286A (en) Razing set
AU5514686A (en) Piperazinecarboxamides
AU5606586A (en) Pseudopterosin and derivatives
AU5392186A (en) Picfilcylinder
AU6518486A (en) Peptides and compositions
AU4538285A (en) Recombinant factor viii-r
AU563024B2 (en) Dihydropyridien
AU5352786A (en) Nasen-kapseln
AU6243686A (en) Improvements in electrostatic-precipitation
AU5452286A (en) Wellenenergieanlage
AU4805485A (en) Schlauchbeutelpackung
AU610821B2 (en) Recombinant inhibin
AU5352386A (en) Vedenalainen tartuntamenetelma ja-valine
AU4001785A (en) Substituted isochromanes and oxepines